Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Advises Medication Error Risk Assessment Early In Development

This article was originally published in The Tan Sheet

Executive Summary

FDA’s draft guidance on safety considerations for product and container design to minimize medication errors calls for assessments in “real world” settings early in the development process. Relying solely on clinical trials is inadequate for a number of factors the agency and sponsors need to know about a new drug product, the draft says.

You may also be interested in...



Regulatory News In Brief

FDA issues guidance on splitting tablets

In Brief

FDA releases drug patch guidance

FDA Gets Strict On Liquid OTC Dosing Devices In Draft Guidance

Some drug firms may need to alter their product packaging and labeling to comply with FDA's guidance on dosing device labeling for liquid OTCs

Topics

UsernamePublicRestriction

Register

LL1135975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel